Deal facts
- Buyer
- American Type Culture Collection, Inc.
- Target
- Lifeline Cell Technology, LLC
- Deal value
- Not disclosed
- Announced
- 10 July 2026
- Status
- Completed
- Sector
- Healthcare
- Country
- United States
- Consideration
- Not stated
Sources
American Type Culture Collection, Inc. has agreed to acquire Lifeline Cell Technology, LLC in a strategic acquisition within the healthcare sector. The transaction was announced on 10 July 2026 and completed on 1 September 2026. Both entities are based in the United States. The financial value of the deal was not disclosed, and no specific currency or consideration type was reported by the parties involved. This acquisition represents a consolidation within the US healthcare market, bringing together two organisations operating in related fields without public disclosure of the monetary terms or the specific strategic rationale behind the combination.
The deal structure is classified as a standard strategic acquisition rather than a management buyout, buy-in, or merger of equals. No other buyers or competitors were mentioned in the available data. The transaction has been finalised and is no longer pending regulatory review or shareholder approval. The completion date confirms that all necessary steps for the transfer of ownership have been executed. This summary provides the essential factual framework for understanding the scope and timing of the acquisition, focusing solely on the reported entities, dates, and sector classification without speculation on future performance or integration plans.
More M&A Tools
Explore the Toolkit
Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.
Access nowDeal timeline
1 update- CompletedClosed
American Type Culture Collection, Inc. completes acquisition of Lifeline Cell Technology, LLC
Item 2.01 Completion of Acquisition or Disposition of Assets. As previously disclosed, on July 10, 2026, International Stem Cell Corporation, a Delaware corporation (the “Company” or “Parent”), International Stem Cell Corporation, a California corporation (“Intermediate” and, together with Parent, “Seller”), Lifeline Cell Technology, LLC, a California limited liability company (“LCT”), and America
Source
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Cronos Group Inc. to acquire CanAdelaar B.V.
Cronos Group Inc. has agreed to acquire CanAdelaar B.V. in a strategic acquisition within the healthcare sector. The Canadian buyer will purchase the Dutch target for a…
- Buyer
- Cronos Group Inc.
- Target
- CanAdelaar B.V.
- Deal value
- EUR 57,500,000
- Deal type
- strategic acquisition
Alaunos Therapeutics, Inc. to acquire Velaris Therapeutics, Inc.
Alaunos Therapeutics, Inc. has agreed to acquire Velaris Therapeutics, Inc. in a strategic acquisition. The transaction was announced on 13 October 2026 and was complete…
- Buyer
- Alaunos Therapeutics, Inc.
- Target
- Velaris Therapeutics, Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
STERIS Corporation to acquire Xodus Medical, Inc.
STERIS Corporation has agreed to acquire Xodus Medical, Inc. in a strategic transaction valued at two billion US dollars. The healthcare deal was announced on 11 October…
- Buyer
- STERIS Corporation
- Target
- Xodus Medical, Inc.
- Deal value
- USD 2,100,000,000
- Deal type
- strategic acquisition
Hepion Pharmaceuticals, Inc. to acquire Gravitas Life Sciences, LLC
Hepion Pharmaceuticals, Inc. has agreed to acquire Gravitas Life Sciences, LLC in a strategic acquisition. The transaction, valued at 4.25 million US dollars, was comple…
- Buyer
- Hepion Pharmaceuticals, Inc.
- Target
- Gravitas Life Sciences, LLC
- Deal value
- USD 4,250,000
- Deal type
- strategic acquisition
Buyer history
American Type Culture Collection, Inc.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive